Fig. 1: Correlations between NY-ESO-1 expression and survival probability in different cancer cohorts. | Cell Death & Disease

Fig. 1: Correlations between NY-ESO-1 expression and survival probability in different cancer cohorts.

From: NY-ESO-1 facilitates anoikis resistance and tumor metastasis by hijacking deubiquitinase OTUB1 to stabilize PP1α

Fig. 1

A The survival plots for breast cancer patients (systemically untreated patients, n = 1025), lung cancer patients (n = 2166), gastric cancer patients (n = 875), and myeloma patients (n = 1416) with or without NY-ESO-1 (217339_x_at) expression were generated via Kaplan–Meier Plotter, RFS Relapse-free survival, OS Overall survival. B, C The survival plots for ovarian cancer patients (n = 1435) and colon cancer patients (n = 1302) with or without NY-ESO-1 (217339_x_at) expression. Correlations between NY-ESO-1 expression and survival probability in the entire cohorts (middle panels) as well as in immune-cold (CD8low) and immune-hot (CD8high) subgroups (left and right panels, respectively) were shown. CD8low expression value below median, CD8high expression value above median, PFS Progression-free survival. D Correlations between NY-ESO-1 expression and survival probability in the entire TNBC cohorts (upper panel) as well as TNBC IM-subtype, IM Immunomodulatory subtype. For (A–C), the Hazard ratio (HR) and P-value for each association are shown within each plot.

Back to article page